2Feldmann M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. Ann Rev Immunol, 1996, 14: 397-440.
3Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type Ⅱ collagen-induced arthritis in mice. J Immunol,1993, 151: 6602-6607.
4Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 6: 727-735.
5Felson DT, Anderson JJ, Boers M, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38:727-735.
6American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum, 1996, 39: 713.
7Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. New Engl J Med, 1994, 330: 1369-1375.
8Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. New Engl J Med, 1997, 337: 195-197.
9Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of Etanercept and methotrexate in patients with early rheumatoid arthritis. New Eng J Med, 2000, 343: 1586-1593.
10Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol,2001, 28: 1238-1244.
9Smolen J;Kalden J;Scott D.k Efficacy and safety of leflunomide compared with placebo and sulphasalazline in active rheumatoid arthritis:a double-blind randomized multicentre trial,1999(9149).
10Kremer J;Caldwell J;Cannon G.The combination of Leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on MTX treatment alone: a double-blind placebo controlled study,2000.
